Detailed Information
Cited 5 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
- Authors
- Kumar, R.; Kim, S. H.; Zhong, D.; Lu, S.; Cheng, Y.; Chen, M.; Cho, E.; Clay, T.; Kang, J. -H.; Lee, G. -W.; Sun, M.; Shim, B. -Y.; Spigel, D. R.; Yang, T. -Y.; Wang, Q.; Chang, G. -C.; Yu, G.; Wang, R.; Luo, X.; Zheng, H.; Gao, R.; Kim, H. R.
- Issue Date
- Sep-2022
- Publisher
- Elsevier Inc.
- Keywords
- TIGIT antibody; PD-1 inhibitor; metastatic NSCLC
- Citation
- Journal of Thoracic Oncology, v.17, no.9, pp S375 - S376
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of Thoracic Oncology
- Volume
- 17
- Number
- 9
- Start Page
- S375
- End Page
- S376
- ISSN
- 1556-0864
1556-1380
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.